UV1

Ultimovacs Publishes Positive Long-term UV1 Data from Phase I Malignant Melanoma Combination Study in Frontiers in Immunology

Retrieved on: 
Tuesday, May 11, 2021
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Drugs, Bristol-Myers Squibb, Cancer immunotherapy, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Nivolumab, Ipilimumab, Checkpoint inhibitor, Melanoma, UV1, UV1 Clinical Programs, Ultimovacs, UV1, UV1 CLINICAL PROGRAMS, ULTIMOVACS

The INITIUM trial is an Ultimovacs-sponsored clinical trial recruiting 154 patients with metastatic malignant melanoma to evaluate UV1 in combination with ipilimumab and nivolumab as first-line treatment.

Key Points: 
  • The INITIUM trial is an Ultimovacs-sponsored clinical trial recruiting 154 patients with metastatic malignant melanoma to evaluate UV1 in combination with ipilimumab and nivolumab as first-line treatment.
  • The NIPU study is testing UV1 in combination with checkpoint inhibitors ipilimumab and nivolumab as second-line treatment in 118 patients with advanced malignant pleural mesothelioma, a rare lung cancer.
  • The study is sponsored by Oslo University Hospital and Bristol-Myers Squibb is providing the checkpoint inhibitors for this study.
  • Ultimovacs\xe2\x80\x99 strategy is to clinically demonstrate UV1\xe2\x80\x99s impact in many cancer types and in combination with other immunotherapies.

Ultimovacs Announces UV1 Data Presentation at Upcoming 2021 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 28, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Vaccination, Branches of biology, Clinical medicine, Medicine, Telomerase reverse transcriptase, Telomerase, Cancer vaccine, Immunotherapy, Vaccine, UV1, Ultimovacs, UV1, ULTIMOVACS

The poster presentation will be available on demand for all conference attendees starting on Friday, June 4th at 9:00 am ET / 3:00 pm CEST.

Key Points: 
  • The poster presentation will be available on demand for all conference attendees starting on Friday, June 4th at 9:00 am ET / 3:00 pm CEST.
  • UV1 is being developed as an \xe2\x80\x9coff-the-shelf\xe2\x80\x9d therapeutic cancer vaccine which may serve as a platform for use in combination with other immunotherapy which requires an ongoing T cell response for their mode of action.
  • Ultimovacs\xe2\x80\x99 lead universal cancer vaccine candidate UV1 leverages the high prevalence of the human telomerase (hTERT) to be effective across the dynamic stages of the tumor\xe2\x80\x99s growth and its microenvironment.
  • Ultimovacs\xe2\x80\x99 strategy is to clinically demonstrate UV1\xe2\x80\x99s impact in many cancer types and in combination with other immunotherapies.

Ultimovacs Announces NIPU Trial Design Poster Presented at World Conference of Lung Cancer Singapore 2020

Retrieved on: 
Thursday, January 28, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Branches of biology, DNA replication, Ribonucleoproteins, Senescence, Telomerase, Vaccination, Cancer vaccine, Tumor microenvironment, Biology, Clinical medicine, UV1, Ultimovacs

Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced that the lead investigator of the Companys NIPU Phase II clinical trial, slaug Helland from Oslo University Hospital, has presented a poster with an overview of the NIPU trial at the 2020 World Conference on Lung Cancer in Singapore.

Key Points: 
  • Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced that the lead investigator of the Companys NIPU Phase II clinical trial, slaug Helland from Oslo University Hospital, has presented a poster with an overview of the NIPU trial at the 2020 World Conference on Lung Cancer in Singapore.
  • For more information on the NIPU trial and the poster that was presented today, please refer to Ultimovacs corporate website.
  • UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
  • Ultimovacs UV1 universal cancer vaccine candidate leverages the high prevalence of the human telomerase (hTERT) to be effective across the dynamic stages of the tumors growth and its microenvironment.

Ultimovacs Announces Phase II DOVACC Collaboration Study in Ovarian Cancer With the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca

Retrieved on: 
Monday, January 11, 2021
Research, Hospitals, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Health sciences, Health, Orphan drugs, Breakthrough therapy, Durvalumab, AstraZeneca, Olaparib, Clinical trial, Gynaecology, European Society of Gynaecological Oncology, UV1, UV1 Clinical Programs, the NSGO-CTU, the ENGOT, Ultimovacs

Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced its participation in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups (ENGOT) and AstraZeneca, to conduct a randomized Phase II clinical trial to evaluate Ultimovacs proprietary universal cancer vaccine, UV1, in combination with AstraZenecas durvalumab and olaparib in patients with relapsed ovarian cancer.

Key Points: 
  • Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced its participation in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups (ENGOT) and AstraZeneca, to conduct a randomized Phase II clinical trial to evaluate Ultimovacs proprietary universal cancer vaccine, UV1, in combination with AstraZenecas durvalumab and olaparib in patients with relapsed ovarian cancer.
  • The collaboration with the NSGO-CTU and ENGOT is exciting for us as they are very experienced with conducting clinical trials in the field of gynaecological oncology.
  • DOVACC is a multi-center, multinational, randomized Phase II clinical trial sponsored by the NSGO, the leading gynaecological oncology research society in the Nordic and Baltic regions.
  • Innovation Norway has granted Ultimovacs NOK 10 million, approximately EUR 1 million, to support the execution of the Phase II DOVACC study.

Ultimovacs Announces Positive 5-Year Overall Survival Update from Phase I Combination Trial Evaluating Universal Cancer Vaccine UV1 in Metastatic Melanoma

Retrieved on: 
Thursday, December 10, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Cancer treatments, Clinical medicine, Medicine, Bristol-Myers Squibb, Antineoplastic drugs, Breakthrough therapy, Ipilimumab, Cancer immunotherapy, Nivolumab, Melanoma, Checkpoint inhibitor, Cancer, UV1, UV1 Clinical Programs, Ultimovacs

Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced positive five-year Overall Survival (OS) data from the Phase I trial evaluating the companys universal cancer vaccine, UV1, in combination with the checkpoint inhibitor, ipilimumab, in patients with metastatic malignant melanoma.

Key Points: 
  • Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced positive five-year Overall Survival (OS) data from the Phase I trial evaluating the companys universal cancer vaccine, UV1, in combination with the checkpoint inhibitor, ipilimumab, in patients with metastatic malignant melanoma.
  • A total of 12 malignant melanoma patients with metastatic disease were treated in the Phase I trial.
  • As a universal cancer vaccine, UV1s unique mechanism of action has the potential to be applicable across most cancer types.
  • The INITIUM trial is an Ultimovacs-sponsored clinical trial recruiting 154 patients with metastatic malignant melanoma to evaluate UV1 in combination with ipilimumab and nivolumab as first-line treatment.

Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer

Retrieved on: 
Monday, October 19, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Clinical medicine, Senescence, Cancer, Telomerase, Small-cell carcinoma, Lung cancer, Non-small-cell lung carcinoma, UV1, UV1 Clinical Programs, Ultimovacs

Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer.

Key Points: 
  • Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer.
  • The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-term survival benefit.
  • Non-small cell lung cancer highly expresses telomerase and remains an indication in great need of new treatment options for patients.
  • As a universal cancer vaccine, UV1s unique mechanism of action has the potential to be applicable across most cancer types.